A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics

Ribeiro, Henrique Caracho; Klassen, Aline; Pedrini, Mariana; Carvalho, Michelle S.; Rizzo, Lucas B.; Noto, Mariane Nunes; Zeni-Graiff, Maiara; Sethi, Sumit; Fonseca, Francisco A.H.; Tasić, Ljubica; Hayashi, Mirian A. F.; Cordeiro, Quirino; Brietzke, Elisa; Sussulini, Alessandra

doi:10.1016/j.psychres.2017.08.039

Cited by 32 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study using dual platform (NMR spectroscopy and GC-MS) revealed 5 urinary metabolite biomarkers with higher accuracy than single-platform derived markers in discriminating bipolar disorder from healthy controls [48]. In another study, an increased proportion of serum sphingolipids and glycerolipids and a decreased proportion of glycerophospholipids were found in bipolar disorder patients when UltraPerformance LC coupled with high-resolution MS was used [49]. However, of the top 5 most differential lipids identified, 3 had unknown biology and could not be identified in any databases [49].…”

Section: Metabolomics Studies Of Common Psychiatric Disordersmentioning

confidence: 99%

“…In another study, an increased proportion of serum sphingolipids and glycerolipids and a decreased proportion of glycerophospholipids were found in bipolar disorder patients when UltraPerformance LC coupled with high-resolution MS was used [49]. However, of the top 5 most differential lipids identified, 3 had unknown biology and could not be identified in any databases [49].…”

Section: Metabolomics Studies Of Common Psychiatric Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics Biomarkers for Precision Psychiatry

Shih

2019

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

The treatment of psychiatric disorders remains a significant challenge in part due to imprecise diagnostic criteria and incomplete understanding of the molecular pathology involved. Current diagnostic and pharmacological treatment guidelines use a uniform approach to address each disorder even though psychiatric clinical presentation and prognosis within a disorder are known to be heterogeneous. Limited therapeutic success highlights the need for a precision medicine approach in psychiatry, termed precision psychiatry. To practice precision psychiatry, it is essential to research and develop multiple omics-based biomarkers that consider environmental factors and careful phenotype determination. Metabolomics, which lies at the endpoint of the "omics cascade," allows for detection of alterations in systems-level metabolites within biological pathways, thereby providing insights into the mechanisms that underlie various physiological conditions and pathologies. The eicosanoids, a family of metabolites derived from oxygenated polyunsaturated fatty acids, play a key role in inflammatory mechanisms and have been implicated in psychiatric disorders such as anorexia nervosa and depression. This review (1) provides background on the current clinical challenges of psychiatric disorders, (2) gives an overview of metabolomics application as a tool to develop improved biomarkers for precision psychiatry, and (3) summarizes current knowledge on metabolomics and lipidomic findings in common psychiatric disorders, with a focus on eicosanoids. Metabolomics is a promising tool for precision psychiatry. This research has great potential for both discovering biomarkers and elucidating molecular mechanisms underlying psychiatric disorders.

show abstract

Section: Metabolomics Studies Of Common Psychiatric Disordersmentioning

confidence: 99%

Section: Metabolomics Studies Of Common Psychiatric Disordersmentioning

confidence: 99%

Metabolomics Biomarkers for Precision Psychiatry

Shih

2019

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…Metabolomics is a research method for qualitative and quantitative analysis of small molecular metabolites in biological samples (11), which is widely used to study the pathological mechanism of complex diseases, such as cancer, diabetes, cardiovascular diseases, and psychiatric diseases, as well as to find new biomarkers for diagnosis and prognosis. Many studies on the metabolomics of BD have been reported, mainly including the study on the diagnostic biomarkers of BD and the changes of metabolites related to drug treatment (12)(13)(14)(15). These studies have found some significant specific metabolites, which need to be verified by more similar studies.…”

Section: Introductionmentioning

confidence: 99%

Pre- and Post-treatment Levels of Plasma Metabolites in Patients With Bipolar Depression

Guo

Cui

et al. 2021

Front. Psychiatry

View full text Add to dashboard Cite

Background: Bipolar disorder (BD) is a serious mental disease with complex clinical manifestations and high recurrence rate. The purpose of this study was to detect metabolites related to the diagnosis and efficacy evaluation of bipolar depression in plasma samples by metabolomics.Methods: Thirty-one bipolar depression patients were recruited and completed 8 weeks medication and a matched group of 47 healthy controls (HCs) was recruited. Nuclear magnetic resonance spectroscopy was used to profile plasma samples of bipolar depression patients at baseline and after 8 weeks medication, and HCs. Then Multivariate statistical analysis was performed to analyze differences of plasma metabolites among the three groups.Results: We detected seven specific differential metabolites in bipolar depression. Six of the metabolites were returned to the normal levels in different degrees after 8 weeks medication, only Glycine continuously decreased in the acute and significant improvement stages of bipolar depression (VIP > 1 and p < 0.05). These differential metabolites involved several metabolic pathways.Limitations: The small sample size was one of the most prominent limitations. Each BD patient was given an individualized medication regimen according to the clinical guidelines.Conclusion: There were metabolites changes before and after 8 weeks medication. Glycine may be a characteristic marker of bipolar depression and does not change with the improvement of bipolar depression, while other 6 differential metabolites may be biomarkers associated with the pathological development or the improvement of bipolar depression. And, these differential metabolites mainly related to energy metabolism, amino acid metabolism and gut microbiota metabolism.

show abstract

“…Peripheral blood has been the focus of biomarker research because of its easy access, quanti able and economic characteristics. Previous studies have shown that patients with BD and UD have different in ammatory characteristics, metabolic biomarkers and oxidative stress markers in peripheral blood [18][19][20][21].In addition, the decrease of bilirubin level in MDD and the increase of serum lactic acid level in BD are also clues for differential diagnosis [22,23].Uric acid is the nal product of purine metabolism and is produced by xanthine dehydrogenase. The increase of uric acid level is related to the accelerated transformation of purine and the decrease of adenosine transmission [24].There is research evidence that the damage of purinergic system plays a certain role in the pathophysiology of mood disorders, namely BD and UD [25].Previous studies reported different results about the uric acid level in patients with UD and BD.The results of a meta-analysis showed that uric acid levels in patients with MDD were signi cantly lower than those in healthy controls [26].A cross-sectional control study found that there was no difference in serum UA between patients with bipolar depression and patients with MDD [27], but the results of Wen et al [28] were inconsistent with this.…”

Section: Introductionmentioning

confidence: 99%

The Serum Uric Acid Level of Bipolar Depression: A Retrospective Real-World Study

Liu

Lei

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective The aim of this study was to evaluate whether serum uric acid can be used as a biomarker to identify bipolar disorder (BD) from unipolar depression (UD). Methods We reviewed the medical records of 18-65-year-old depressive patients hospitalized in the first hospital of Shanxi Medical University from October 2015 to October 2020. The main discharge diagnosis of these patients was recurrent depressive disorder(RDD) or BD. The data of gender, age, education level, drug use and serum uric acid level were extracted. The differences of uric acid levels between the two groups at admission and discharge were compared. Results The uric acid level of BD decreased after treatment, the uric acid level of BD group was significantly higher than that of UD group at baseline (P=0.02) and after treatment (P=0.025). Conclusion UA may be a potential biomarker to distinguish BD from UD.

show abstract

A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics

Cited by 32 publications

References 35 publications

Metabolomics Biomarkers for Precision Psychiatry

Metabolomics Biomarkers for Precision Psychiatry

Pre- and Post-treatment Levels of Plasma Metabolites in Patients With Bipolar Depression

The Serum Uric Acid Level of Bipolar Depression: A Retrospective Real-World Study

Contact Info

Product

Resources

About